Company Overview and News

 
Alkem Laboratories Limited - Disc. under Reg.30 of SEBI (SAST) Reg.2011

2018-04-17 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.

 
Global fall drags Sensex 206 pts; Nifty50, Bank indices close March series 2.6% lower

2018-03-28 moneycontrol
The market closed the last day of financial year 2017-18 on a weak note Wednesday after gains seen in previous two consecutive sessions, tracking global weakness. All sectoral indices ended in the red barring IT.

 
Alkem Labs gets 14 USFDA observations for two units, shares fall 11%

2018-03-28 livemint
New Delhi: Alkem Laboratories Ltd on Wednesday said that the US Food and Drug Administration (USFDA) has pointed out 14 observations for objectionable conditions at its manufacturing units at Amaliya in Daman and St Louis in US following inspections.

 
Alkem Laboratories falls 11% as USFDA issues 13 observations to Daman plant

2018-03-28 moneycontrol
Alkem Laboratories share price plunged as much as 11 percent in afternoon Wednesday after the US health regulator issued 13 observations to Daman facility and 1 to US plant.

 
Alkem Laboratories Limited - Press Release

2018-03-28 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.

 
Eight Indian women in Forbes ‘World’s Billionaires’ list

2018-03-08 freepressjournal.in
New Delhi: Eight Indian women have featured in this year’s Forbes list of the world’s richest people. Forbes’ 2018 ‘World’s Billionaires’ list includes a total of 256 women, an all-time high, and their collective net worth topped USD 1 trillion, up 20 per cent since last year. Though most of the women at the top of the list inherited their fortunes, the number of self-made women reached 72 for the first time, up from 56 a year ago, Forbes said.

 
Paytm’s Vijay Shekhar Sharma youngest Indian billionaire: Forbes

2018-03-07 livemint
New Delhi: Paytm founder Vijay Shekhar Sharma, 39, is the youngest Indian billionaire, while 92-year-old Samprada Singh, chairman emeritus of Alkem Laboratories Ltd, is the oldest, according to Forbes magazine.

 
Pharma weekly wrap: Lupin, Glenmark post nos; Singh brothers resign from Fortis board

2018-02-10 moneycontrol
Pharma stocks recovered this past week after budget week lows, despite weakness of benchmark index. The investors took advantage of relatively cheap valuations of pharma shares. The highlights of the week include resignation of Malvinder and Shivinder Singh, promoters of Fortis, from the Board and Q3 results of some major pharmaceutical companies. With exception of Cadila Healthcare, Aurobindo Pharma and Cipla – the rest of pack had posted disappointing Q3 numbers as they struggled with pricing pressures in US market.

 
Alkem Lab Q3 net profit down 23 percent at Rs 181 crore

2018-02-09 moneycontrol
Alkem Laboratories today reported a 23.44 percent decline in its consolidated net profit at Rs 180.87 crore for the quarter ended December 2017 on higher tax expenses.

 
Market Live: Sensex, Nifty Bank fall around 400 pts; Midcap index extends gains

2018-02-09 moneycontrol
3:02 pm Buzzing: Hotel Leela Venture shares were locked at 20 percent upper circuit after the company turned profitable with Q3 net income at Rs 40.6 crore against loss of Rs 10.4 crore in year-ago, led by other income.

 
Market Live: Sensex flirts with 34K, slips 400 pts; Midcap index turns positive

2018-02-09 moneycontrol
2:06 pm Earnings: R Systems International shares gained 12.5 percent despite the consolidated profit in Q3 fell 56.2 percent to Rs 8.1 crore YoY due to weak operational performance.

 
Market Live: Sensex flirts with 34K, slips 400 pts; midcaps off day#39;s low

2018-02-09 moneycontrol
1:05 pm Stake Buy: Sources told CNBC-TV18 that global PE investor Blackstone is in talks to buy equity stake in SPV holding, Indiabulls Real Estate's commercial assets and to infuse close to USD 500 million in Indiabulls Real.

 
Market Live: Sensex slips over 450 pts, Midcap outperforms; Tata Steel, Lupin gain

2018-02-09 moneycontrol
11:15 am Market Update: Frontline indices were trading near day's low in late morning deals as the Sensex was down 517.63 points or 1.50 percent at 33,895.53 and the Nifty fell 163.50 points or 1.55 percent to 10,413.40.

 
Market Live: Sensex set to open sharply lower on global fall; Asia, US down 2-5%

2018-02-09 moneycontrol
9:05 am Rupee Trade: The Indian rupee was trading at 64.39 to the dollar, down 13 paise compared to previous close.

Related Articles

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

AGEN: Agenus Inc Analysis and Research Report

2018-05-21 - Asif

Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...

SQ: Square Analysis and Research Report

2018-05-21 - Asif

Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...